13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773195
Total reported value
$2.2B
$2.2B
91 檔
15.2%
In Q2 2024, Affinity Asset Advisors, LLC's U.S. equity holdings reached a combined market value of $2.2B, distributed across 91 disclosed stock positions.
During Q2 2024, Affinity Asset Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 21.96% | -6.72% | EXIT | |
| 2 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 4.87% | -1.61% | -14.89% | |
| 3 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.47% | -0.68% | +18.73% | |
| 4 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.79% | +0.33% | +41.24% | |
| 5 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 3.55% | -0.52% | -4.35% | |
| 6 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 3.54% | — | +150.00% | |
| 7 | ACLXGBX | Arcellx Inc | Stock-Other | 2.93% | -2.15% | EXIT | |
| 8 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 2.66% | -0.01% | +9.57% | |
| 9 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.19% | +0.29% | +12.56% | |
| 10 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.03% | +0.36% | -6.78% | |
| 11 | BBIO 2.5 03-15-27Bond | Bridgebio Pharma Inc | Bond | 1.99% | — | — | |
| 12 | ALNY 1 09-15-27Bond | Alnylam Pharmaceuticals | Bond | 1.87% | — | +50.00% | |
| 13 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.81% | — | +33.91% | |
| 14 | ALKS | Alkermes plc | Stock-Healthcare | 1.81% | +0.79% | +766.67% | |
| 15 | NUVL | Nuvalent Inc-a | Stock-Other | 1.75% | -0.05% | +33.33% | |
| 16 | AUTL | Autolus Therapeutics PLC | Stock-Other | 1.72% | — | +27.41% | |
| 17 | VERA | Vera Therapeutics Inc | Stock-Other | 1.56% | -0.04% | -20.21% | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 1.54% | — | -11.02% | |
| 19 | ✓ | Inozyme Pharma Inc | Stock-Other | 1.47% | — | +8.09% | |
| 20 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.39% | +1.80% | +25.22% | |
| 21 | CLYM | Climb Bio Inc | Stock-Other | 1.37% | +0.32% | — | |
| 22 | IMVT | Immunovant Inc | Stock-Other | 1.22% | +0.04% | -6.76% | |
| 23 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.18% | -2.87% | EXIT | |
| 24 | ✓ | Establishment Labs Holdings In | Stock-Other | 1.17% | +0.28% | +4.11% | |
| 25 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.17% | — | -14.41% | |
| 26 | NARIUSD | Inari Medical Inc | Stock-Other | 1.11% | — | +14.29% | |
| 27 | INSM | Insmed Inc | Stock-Healthcare | 1.03% | -0.92% | — | |
| 28 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.02% | — | +15.37% | |
| 29 | CHRS 1.5 04-15-26Bond | Coherus Oncology Inc | Bond | 1.00% | — | +30.56% | |
| 30 | MORFUSD | Morphic Holding Inc | Stock-Other | 0.98% | — | +11.37% | |
| 31 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.94% | -0.03% | +47.85% | |
| 32 | OMER 5.25 02-15-26Bond | Omeros CORP | Bond | 0.93% | — | +9.05% | |
| 33 | RZLT | Rezolute Inc | Stock-Other | 0.92% | — | +15.63% | |
| 34 | ✓ | Merus N V | Stock-Other | 0.85% | — | — | |
| 35 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.74% | — | -42.76% | |
| 36 | GERN | Geron CORP | Stock-Other | 0.73% | — | -40.00% | |
| 37 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 0.73% | — | — | |
| 38 | SVRA | Savara Inc | Stock-Other | 0.72% | -0.01% | +34.51% | |
| 39 | ERAS | Erasca Inc | Stock-Other | 0.68% | -0.12% | — | |
| 40 | PCVX | Vaxcyte Inc | Stock-Other | 0.65% | — | -6.25% | |
| 41 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.63% | -0.03% | — | |
| 42 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.61% | — | -3.13% | |
| 43 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.53% | +0.15% | +2.02% | |
| 44 | ✓ | Elevation Oncology Inc | Stock-Other | 0.46% | — | +15.76% | |
| 45 | ✓ | Hillevax Inc | Stock-Other | 0.44% | — | — | |
| 46 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.44% | -0.14% | — | |
| 47 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.43% | +1.99% | -29.68% | |
| 48 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.41% | — | — | |
| 49 | ✓ | Stock-Other | 0.41% | — | — | ||
| 50 | ✓ | Immatics NV | Stock-Other | 0.40% | — | -14.29% |
According to official SEC Form 13F filings, Affinity Asset Advisors, LLC reported a total U.S. public equity portfolio value of $2.2B across 91 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, TEVA, XENE) accounted for 15.2% of total reported equity market value during Q2 2024.
During Q2 2024, Affinity Asset Advisors, LLC's top holdings by market value included SPY (22.0%)、TEVA (4.9%)、XENE (4.5%). The largest single position, SPY, represented 22.0% of total portfolio value.
In Q2 2024, Affinity Asset Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.